ZA200808597B - Antibodies against insulin-like growth factor I receptor and uses thereof - Google Patents

Antibodies against insulin-like growth factor I receptor and uses thereof

Info

Publication number
ZA200808597B
ZA200808597B ZA200808597A ZA200808597A ZA200808597B ZA 200808597 B ZA200808597 B ZA 200808597B ZA 200808597 A ZA200808597 A ZA 200808597A ZA 200808597 A ZA200808597 A ZA 200808597A ZA 200808597 B ZA200808597 B ZA 200808597B
Authority
ZA
South Africa
Prior art keywords
receptor
growth factor
antibodies against
against insulin
insulin
Prior art date
Application number
ZA200808597A
Other languages
English (en)
Inventor
Hansen Silke
Kuenkele Klaus-Peter
Reusch Dietmar
Schumacher Ralf
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36940705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200808597(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200808597B publication Critical patent/ZA200808597B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200808597A 2006-04-11 2008-10-08 Antibodies against insulin-like growth factor I receptor and uses thereof ZA200808597B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06007571 2006-04-11

Publications (1)

Publication Number Publication Date
ZA200808597B true ZA200808597B (en) 2009-11-25

Family

ID=36940705

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200808597A ZA200808597B (en) 2006-04-11 2008-10-08 Antibodies against insulin-like growth factor I receptor and uses thereof

Country Status (20)

Country Link
US (1) US20080014203A1 (cg-RX-API-DMAC7.html)
EP (2) EP2363417A1 (cg-RX-API-DMAC7.html)
JP (1) JP4718634B2 (cg-RX-API-DMAC7.html)
KR (2) KR20120028396A (cg-RX-API-DMAC7.html)
CN (1) CN101421305B (cg-RX-API-DMAC7.html)
AR (1) AR060592A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007236199B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0710185B8 (cg-RX-API-DMAC7.html)
CA (2) CA2647181C (cg-RX-API-DMAC7.html)
CR (1) CR10301A (cg-RX-API-DMAC7.html)
EC (1) ECSP088816A (cg-RX-API-DMAC7.html)
ES (1) ES2403075T3 (cg-RX-API-DMAC7.html)
IL (1) IL194397A (cg-RX-API-DMAC7.html)
MX (1) MX2008012950A (cg-RX-API-DMAC7.html)
NO (1) NO20084082L (cg-RX-API-DMAC7.html)
NZ (1) NZ571414A (cg-RX-API-DMAC7.html)
RU (1) RU2541765C2 (cg-RX-API-DMAC7.html)
UA (1) UA95284C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007115814A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200808597B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
AR064464A1 (es) * 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
CN101903401B (zh) 2007-12-21 2013-06-05 罗切格利卡特公司 抗体的稳定性试验
PT2376116E (pt) 2008-12-12 2016-02-24 Boehringer Ingelheim Int Anticorpos anti-igf
WO2010112194A1 (en) * 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
EP2456547B2 (en) 2009-07-24 2024-03-06 F. Hoffmann-La Roche AG Stirrer system
CA2774953A1 (en) * 2009-10-07 2011-04-14 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Human domain antibodies against components of the human insulin-like growth factor (igf) system
JP5711751B2 (ja) 2009-10-26 2015-05-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ グリコシル化された免疫グロブリンの調製方法
WO2011101328A2 (en) 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
WO2011135040A1 (en) 2010-04-30 2011-11-03 F. Hoffmann-La Roche Ag Fluorescent antibody fusion protein, its production and use
MX342235B (es) 2010-11-05 2016-09-21 Hoffmann La Roche Metodo optimizado para captura de anticuerpo por cromatografia de modo mixto.
MX354663B (es) 2011-06-22 2018-03-14 Hoffmann La Roche Eliminación de células diana por parte de células t citotóxicas específicas de virus utilizando complejos que comprenden mhc de clase i.
RU2502798C2 (ru) * 2012-02-22 2013-12-27 Общество с ограниченной ответственностью "Фармако Биотех" КЛЕТОЧНАЯ ЛИНИЯ huFSHIK, СЕКРЕТИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ЧЕЛОВЕЧЕСКИЙ ФСГ
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
RU2015129640A (ru) 2012-12-21 2017-01-26 Ф.Хоффманн-Ля Рош Аг Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
WO2021119234A1 (en) * 2019-12-10 2021-06-17 Horizon Pharma Ireland Ltd. Glycosylated antibodies against insulin-like growth factor i receptor and uses thereof
CN119792512A (zh) 2020-10-14 2025-04-11 维里迪安治疗公司 用于治疗甲状腺眼病的组合物和方法
US20230084477A1 (en) 2021-08-10 2023-03-16 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5650508A (en) * 1991-12-27 1997-07-22 Georgia Tech Research Corporation Peptide ketoamides
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
PT1176195E (pt) * 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
NZ571508A (en) * 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
ES2383014T3 (es) * 2003-04-02 2012-06-15 F. Hoffmann-La Roche Ag Anticuerpos contra el factor I de crecimiento similar a insulina y usos de los mismos
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
JPWO2005014651A1 (ja) * 2003-08-11 2006-11-24 中外製薬株式会社 糖鎖改変抗ｈｍ１．２４抗体
WO2005034994A1 (ja) * 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 固形腫瘍治療剤

Also Published As

Publication number Publication date
EP2007810B1 (en) 2013-02-13
BRPI0710185B8 (pt) 2021-05-25
JP2009533367A (ja) 2009-09-17
CA3081707A1 (en) 2007-10-18
RU2008144290A (ru) 2010-05-20
CA2647181C (en) 2020-08-11
EP2363417A1 (en) 2011-09-07
KR101276513B1 (ko) 2013-06-21
US20080014203A1 (en) 2008-01-17
IL194397A (en) 2014-04-30
ECSP088816A (es) 2008-11-27
AU2007236199A1 (en) 2007-10-18
CA2647181A1 (en) 2007-10-18
BRPI0710185A8 (pt) 2019-01-22
BRPI0710185B1 (pt) 2020-01-14
IL194397A0 (en) 2011-08-01
NO20084082L (no) 2008-11-06
AR060592A1 (es) 2008-07-02
JP4718634B2 (ja) 2011-07-06
MX2008012950A (es) 2008-10-15
CR10301A (es) 2008-10-29
CN101421305A (zh) 2009-04-29
CN101421305B (zh) 2013-05-15
ES2403075T3 (es) 2013-05-13
RU2541765C2 (ru) 2015-02-20
NZ571414A (en) 2011-12-22
UA95284C2 (ru) 2011-07-25
KR20120028396A (ko) 2012-03-22
KR20080113233A (ko) 2008-12-29
WO2007115814A2 (en) 2007-10-18
EP2007810A2 (en) 2008-12-31
WO2007115814A3 (en) 2008-01-10
BRPI0710185A2 (pt) 2011-08-09
AU2007236199B2 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
IL198778A0 (en) Antibodies against insulin-like growth factor i receptor and uses thereof
ZA200808597B (en) Antibodies against insulin-like growth factor I receptor and uses thereof
IL240245A0 (en) Antibodies against 5t4 and their uses
IL195658A0 (en) Anti-nkg2a antibodies and uses thereof
IL194266A0 (en) Anti-igf-ir antibodies and uses thereof
ZA201003025B (en) Anti-hepcidin antibodies and uses thereof
IL200012A0 (en) Anti-robo4 antibodies and uses therefor
IL196397A0 (en) Prlr-specific antibody and uses thereof
SI2099826T1 (sl) Anti-beta-amiloidno protitelo in njegova uporaba
IL192419A0 (en) Anti-ephb4 antibodies and methods using same
GB0601102D0 (en) Kinase Peptides And Antibodies
IL231891A0 (en) Anti-2ephriinb antibodies and methods of using them
ZA201103941B (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
IL203073A0 (en) Modified growth hormone polypeptides
ZA200806053B (en) Anti-EphB4 antibodies and methods using same
AU2006900785A0 (en) Antibodies to insulin-like growth factor I receptor
ZA200905136B (en) Anti-robo4 antibodies and uses therefor
HK1145505A (en) Anti-chikungunya monoclonal antibodies and uses thereof
GB0607376D0 (en) Antibodies
GB0606276D0 (en) Antibodies
HK1137179A (en) Anti-robo4 antibodies and uses therefor